<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706719</url>
  </required_header>
  <id_info>
    <org_study_id>ZA-201</org_study_id>
    <nct_id>NCT00706719</nct_id>
  </id_info>
  <brief_title>To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone</brief_title>
  <official_title>A Randomized, Open-Label, Fixed Dose, Active-Control, Multi-Center Phase IIB Study to Evaluate Fertility in Men With Secondary Hypogonadism, Comparing Androxal® to a Topical Testosterone in Men Previously Treated With Topical Testosterone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to determine if Androxal® would affect sperm parameters (count,
      concentration, volume) in men with secondary hypogonadism who have been previously treated
      with topical testosterone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was designed to determine if Androxal® would affect sperm parameters (count,
      concentration, volume) in men with secondary hypogonadism who have been previously treated
      with topical testosterone. A maximum of twelve subjects per group were randomized to daily
      treatments of Androxal® or topical testosterone (Testim®) for six months. The protocol was
      later amended to include a treatment group who received Androxal after a 3 month wash out
      period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sperm Concentration</measure>
    <time_frame>Baseline, Month 3, Month 6, Follow-Up (Month 7)</time_frame>
    <description>Total sperm concentration was measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motile Total Sperm Count</measure>
    <time_frame>Baseline, Month 3, Month 6, Follow-Up (Month 7)</time_frame>
    <description>Motile total sperm count was measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semen Volume</measure>
    <time_frame>Baseline, Month 3, Month 6, Follow-Up (Month 7)</time_frame>
    <description>Semen volume was measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Luteinizing Hormone (LH) Levels</measure>
    <time_frame>Baseline, Month 3, Month 6, Follow-Up (Month 7)</time_frame>
    <description>LH levels were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone (FSH) Levels</measure>
    <time_frame>Baseline, Month 3, Month 6, Follow-Up (Month 7)</time_frame>
    <description>FSH levels were measured.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Secondary Hypogonadism</condition>
  <arm_group>
    <arm_group_label>25 mg Androxal no wash out</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 capsule daily for 6 months of 25 mg of Androxal in men without a 3 month wash out period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testim 1% (topical testosterone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testim 1% Gel applied topically for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg Androxal wash out</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x 25 mg Androxal capsule daily for 6 months in men with a previous 3 month washout period of topical testosterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 mg Androxal</intervention_name>
    <description>25 mg Androxal capsules, 1 capsule daily for 6 months</description>
    <arm_group_label>25 mg Androxal no wash out</arm_group_label>
    <arm_group_label>25 mg Androxal wash out</arm_group_label>
    <other_name>Enclomiphene citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testim 1%</intervention_name>
    <description>Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months</description>
    <arm_group_label>Testim 1% (topical testosterone)</arm_group_label>
    <other_name>Topical testosterone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males between 21 and 60 years of age who have been diagnosed with AIHH.

          -  Subjects must have been treated with a topical testosterone replacement therapy
             (typically AndroGel® or Testim®) for at least 6 months at enrollment and for not more
             than 2 years.

        Exclusion Criteria:

          -  A history of idiopathic infertility due to primary hypogonadism, testicular failure,
             Kallmann's syndrome or any other infertility condition.

          -  Subjects demonstrating any clinically significant medical condition rendering the
             subjects infertile or marginally fertile other than AIHH.

          -  Men with a history of, known, or suspected prostate disease not ruled out by a
             prostate biopsy, or a prostate specific antigen (PSA)&gt;3.6 or clinical suspicion of
             current prostate disease.

          -  Men with a hematocrit in excess of 50 % or hemoglobin &gt;17 g/dl
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Wiehle, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Repros Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Urology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAZE Labs</name>
      <address>
        <city>Purchase</city>
        <state>New York</state>
        <zip>10577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <results_first_submitted>August 25, 2010</results_first_submitted>
  <results_first_submitted_qc>September 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 8, 2010</results_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult Onset Idiopathic Hypothalamic Hypogonadism (AIHH)</keyword>
  <keyword>Secondary hypogonadism</keyword>
  <keyword>Semen volume</keyword>
  <keyword>Sperm count</keyword>
  <keyword>Sperm motility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A Testim (Topical Testosterone)</title>
          <description>1% Testim gel applied once daily</description>
        </group>
        <group group_id="P2">
          <title>Group B Androxal no Washout</title>
          <description>25 mg Androxal capsules once daily in men who have not previously washed out topical testosterone</description>
        </group>
        <group group_id="P3">
          <title>Group C Androxal With Wash Out</title>
          <description>25 mg capsules once daily in men who have previously had a 3 month wash out of topical testosterone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A Testim</title>
          <description>1% Testim gel applied daily</description>
        </group>
        <group group_id="B2">
          <title>Group B Androxal no Wash Out</title>
          <description>25 mg Androxal 1 capsule per day in men who have not previously washed out topical testosterone for 3 months</description>
        </group>
        <group group_id="B3">
          <title>Group C Androxal Wash Out</title>
          <description>25 mg 1 capsule per day in men who have undergone a 3 month wash out period of topical testosterone</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="4.88"/>
                    <measurement group_id="B2" value="48.9" spread="8.99"/>
                    <measurement group_id="B3" value="56.4" spread="23.8"/>
                    <measurement group_id="B4" value="52.7" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sperm Concentration</title>
        <description>Total sperm concentration was measured.</description>
        <time_frame>Baseline, Month 3, Month 6, Follow-Up (Month 7)</time_frame>
        <population>Subjects in Group A and B who completed the study. No analysis was performed for subjects in Group C because only 1 subject completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A Testim</title>
            <description>1% Testim gel applied daily</description>
          </group>
          <group group_id="O2">
            <title>Group B Androxal no Wash Out</title>
            <description>25 mg Androxal 1 capsule per day in men who have not previously washed out topical testosterone for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Sperm Concentration</title>
          <description>Total sperm concentration was measured.</description>
          <population>Subjects in Group A and B who completed the study. No analysis was performed for subjects in Group C because only 1 subject completed the study.</population>
          <units>millions sperm/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.74"/>
                    <measurement group_id="O2" value="72.8" spread="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="5.20"/>
                    <measurement group_id="O2" value="182.6" spread="115.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.14" spread="30.67"/>
                    <measurement group_id="O2" value="168.5" spread="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up (Month 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.03" spread="28.90"/>
                    <measurement group_id="O2" value="164.0" spread="71.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.118</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Month 3.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Month 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Follow-up (Month 7).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Motile Total Sperm Count</title>
        <description>Motile total sperm count was measured.</description>
        <time_frame>Baseline, Month 3, Month 6, Follow-Up (Month 7)</time_frame>
        <population>Subjects in Group A and B who completed the study. No analysis was performed for subjects in Group C because only 1 subject completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A Testim</title>
            <description>1% Testim gel applied daily</description>
          </group>
          <group group_id="O2">
            <title>Group B Androxal no Wash Out</title>
            <description>25 mg Androxal 1 capsule per day in men who have not previously washed out topical testosterone for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Motile Total Sperm Count</title>
          <description>Motile total sperm count was measured.</description>
          <population>Subjects in Group A and B who completed the study. No analysis was performed for subjects in Group C because only 1 subject completed the study.</population>
          <units>millions sperm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.48"/>
                    <measurement group_id="O2" value="99.0" spread="159.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" spread="5.41"/>
                    <measurement group_id="O2" value="214.7" spread="166.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="55.3"/>
                    <measurement group_id="O2" value="146.9" spread="120.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up (Month 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" spread="52.5"/>
                    <measurement group_id="O2" value="100.3" spread="103.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Month 3.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0067</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Month 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Follow-up (Month 7).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Semen Volume</title>
        <description>Semen volume was measured.</description>
        <time_frame>Baseline, Month 3, Month 6, Follow-Up (Month 7)</time_frame>
        <population>Subjects in Group A and B who completed the study. No analysis was performed for subjects in Group C because only 1 subject completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A Testim</title>
            <description>1% Testim gel applied daily</description>
          </group>
          <group group_id="O2">
            <title>Group B Androxal no Wash Out</title>
            <description>25 mg Androxal 1 capsule per day in men who have not previously washed out topical testosterone for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Semen Volume</title>
          <description>Semen volume was measured.</description>
          <population>Subjects in Group A and B who completed the study. No analysis was performed for subjects in Group C because only 1 subject completed the study.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" spread="1.43"/>
                    <measurement group_id="O2" value="2.23" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="1.40"/>
                    <measurement group_id="O2" value="2.45" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="1.03"/>
                    <measurement group_id="O2" value="2.48" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up (Month 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="0.83"/>
                    <measurement group_id="O2" value="2.40" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.880</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Month 3.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.612</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Month 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.488</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Follow-up (Month 7).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Luteinizing Hormone (LH) Levels</title>
        <description>LH levels were measured.</description>
        <time_frame>Baseline, Month 3, Month 6, Follow-Up (Month 7)</time_frame>
        <population>Subjects in Group A and B who completed the study. No analysis was performed for subjects in Group C because only 1 subject completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A Testim</title>
            <description>1% Testim gel applied daily</description>
          </group>
          <group group_id="O2">
            <title>Group B Androxal no Wash Out</title>
            <description>25 mg Androxal 1 capsule per day in men who have not previously washed out topical testosterone for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Luteinizing Hormone (LH) Levels</title>
          <description>LH levels were measured.</description>
          <population>Subjects in Group A and B who completed the study. No analysis was performed for subjects in Group C because only 1 subject completed the study.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" spread="2.14"/>
                    <measurement group_id="O2" value="2.92" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="1.39"/>
                    <measurement group_id="O2" value="5.70" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.58"/>
                    <measurement group_id="O2" value="6.12" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up (Month 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="0.48"/>
                    <measurement group_id="O2" value="2.47" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.705</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Month 3.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Month 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Follow-up (Month 7).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.808</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follicle Stimulating Hormone (FSH) Levels</title>
        <description>FSH levels were measured.</description>
        <time_frame>Baseline, Month 3, Month 6, Follow-Up (Month 7)</time_frame>
        <population>Subjects in Group A and B who completed the study. No analysis was performed for subjects in Group C because only 1 subject completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A Testim</title>
            <description>1% Testim gel applied daily</description>
          </group>
          <group group_id="O2">
            <title>Group B Androxal no Wash Out</title>
            <description>25 mg Androxal 1 capsule per day in men who have not previously washed out topical testosterone for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Follicle Stimulating Hormone (FSH) Levels</title>
          <description>FSH levels were measured.</description>
          <population>Subjects in Group A and B who completed the study. No analysis was performed for subjects in Group C because only 1 subject completed the study.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="0.74"/>
                    <measurement group_id="O2" value="1.58" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.12"/>
                    <measurement group_id="O2" value="4.53" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.51"/>
                    <measurement group_id="O2" value="5.48" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up (Month 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.20"/>
                    <measurement group_id="O2" value="2.38" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Month 3.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Month 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Group A and B observed values at Follow-up (Month 7).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group A Testim</title>
          <description>1% Testim gel applied daily</description>
        </group>
        <group group_id="E2">
          <title>Group B Androxal no Wash Out</title>
          <description>25 mg Androxal 1 capsule per day in men who have not previously washed out topical testosterone for 3 months</description>
        </group>
        <group group_id="E3">
          <title>Androxal Wash Out</title>
          <description>25 mg 1 capsule per day in men who have undergone a 3 month wash out period of topical testosterone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Gastrointestinal</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>worsening depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>vasomotor flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Wiehle, PhD</name_or_title>
      <organization>Repros Therapeutics, Inc</organization>
      <phone>281.719.3406</phone>
      <email>rwiehle@reprosrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

